The FDA in Maharashtra has taken a major step against Cadila Pharmaceuticals by halting the sale and distribution of its highly popular acidity and heartburn medication, Aciloc. This regulatory action comes after officials detected critical branding inconsistencies that could mislead consumers and medical professionals. In a state-wide crackdown, the food and drug administration has seized stock valued at approximately Rs 2.45 crore, highlighting the severity of the compliance failure.
Massive Seizure Across Major Maharashtra Distribution Hubs
During targeted inspections conducted on July 9 and July 10, food and drug administration inspectors carried out raids at key warehousing facilities in Pune, Nagpur, and Bhiwandi in Thane district. The coordinated operation resulted in the seizure of drugs worth exactly Rs 2,45,37,490. The action targets specific formulations under the Aciloc brand umbrella, including Aciloc 150, Aciloc 150 Plus, Aciloc 300, and Aciloc 300 Plus. These medications utilize active pharmaceutical ingredients such as ranitidine and famotidine to treat gastric ulcers, acid reflux, and persistent chest burn.
The Core Issue of Misleading Brand Extensions
The regulatory body revealed that Cadila Pharmaceuticals originally held official manufacturing permissions for ranitidine-based tablets, specifically Aciloc 150 and Aciloc 300. However, the drug manufacturer subsequently introduced famotidine-based formulations under the names Aciloc 150 Plus and Aciloc 300 Plus. The company utilized almost identical packaging, color schemes, and brand typography for these new variants. This decision created an environment of extreme confusion, as two entirely different chemical components were being sold under practically identical brand names, posing a significant risk of medication errors.
Strict Directives and Potential Legal Ramifications
FDA Commissioner Tukaram Mundhe emphasized that any degree of similarity in drug brand names that could confuse a prescribing doctor, a dispensing pharmacist, or an end-user patient is a grave threat to public health safety. Consequently, the regulatory authority has ordered Cadila Pharmaceuticals to immediately recall all existing market stock of the affected products. Additionally, the sale of Aciloc 150 Plus and Aciloc 300 Plus has been completely suspended. The department is conducting a detailed investigation into the matter, and once the final findings are compiled, formal legal proceedings will be initiated under the stringent provisions of the Drugs and Cosmetics Act, 1940. Regulators reiterated that introducing altered chemical formulations under nearly identical product names without explicit approval directly violates established drug manufacturing guidelines.
